APA (7th ed.) Citation

Zhang, T., Harrison, M. R., O'Donnell, P. H., Alva, A. S., Hahn, N. M., Appleman, L. J., . . . George, D. J. (2020). A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer. Cancer, 126(20), 4485-4497. https://doi.org/10.1002/cncr.33067

Chicago Style (17th ed.) Citation

Zhang, Tian, et al. "A Randomized Phase 2 Trial of Pembrolizumab Versus Pembrolizumab and Acalabrutinib in Patients with Platinum‐resistant Metastatic Urothelial Cancer." Cancer 126, no. 20 (2020): 4485-4497. https://doi.org/10.1002/cncr.33067.

MLA (9th ed.) Citation

Zhang, Tian, et al. "A Randomized Phase 2 Trial of Pembrolizumab Versus Pembrolizumab and Acalabrutinib in Patients with Platinum‐resistant Metastatic Urothelial Cancer." Cancer, vol. 126, no. 20, 2020, pp. 4485-4497, https://doi.org/10.1002/cncr.33067.